Free Trial
NASDAQ:LEXX

Lexaria Bioscience (LEXX) Stock Price, News & Analysis

$3.14
+0.12 (+3.97%)
(As of 07/24/2024 ET)
Today's Range
$2.94
$3.23
50-Day Range
$2.58
$4.00
52-Week Range
$0.76
$6.85
Volume
380,034 shs
Average Volume
127,634 shs
Market Capitalization
$49.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

Lexaria Bioscience MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
250.3% Upside
$11.00 Price Target
Short Interest
Healthy
1.27% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.55mentions of Lexaria Bioscience in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.43) to ($0.37) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.65 out of 5 stars

Medical Sector

662nd out of 901 stocks

Pharmaceutical Preparations Industry

314th out of 426 stocks

LEXX stock logo

About Lexaria Bioscience Stock (NASDAQ:LEXX)

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

LEXX Stock Price History

LEXX Stock News Headlines

Former Hedge Fund Manager Issues Crash Prediction
Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilson, an extremely rare window in the markets is about to open. It's an often-misunderstood market setup we've only seen 13 times since 1920. The last time this happened, it minted a million brand-new millionaires – in a single year. But Tilson says this unique window in the markets could close much sooner than anyone realizes, leaving most investors in the dust, while making a select few incredibly rich.
Former Hedge Fund Manager Issues Crash Prediction
Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilson, an extremely rare window in the markets is about to open. It's an often-misunderstood market setup we've only seen 13 times since 1920. The last time this happened, it minted a million brand-new millionaires – in a single year. But Tilson says this unique window in the markets could close much sooner than anyone realizes, leaving most investors in the dust, while making a select few incredibly rich.
See More Headlines
Receive LEXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lexaria Bioscience and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
7/24/2024
Fiscal Year End
8/31/2024
Next Earnings (Estimated)
11/19/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:LEXX
Fax
N/A
Employees
5
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.00
High Stock Price Target
$12.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+250.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-6,660,000.00
Pretax Margin
-1,292.04%

Debt

Sales & Book Value

Annual Sales
$230,000.00
Book Value
$0.62 per share

Miscellaneous

Free Float
11,905,000
Market Cap
$49.64 million
Optionable
Not Optionable
Beta
0.99
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Christopher A. Bunka (Age 62)
    Chairman & CEO
    Comp: $291.19k
  • Mr. John M. Docherty M.Sc. (Age 55)
    President & Director
    Comp: $290.46k
  • Mr. Nelson D. Cabatuan CPA (Age 45)
    Chief Financial Officer
  • Kristin Hamilton
    Director of Operations
  • Vanessa Carle
    Head of Legal
  • Dr. Philip N. Ainslie Ph.D.
    Advisor & Consultant

LEXX Stock Analysis - Frequently Asked Questions

How have LEXX shares performed this year?

Lexaria Bioscience's stock was trading at $1.25 on January 1st, 2024. Since then, LEXX shares have increased by 151.2% and is now trading at $3.14.
View the best growth stocks for 2024 here
.

How do I buy shares of Lexaria Bioscience?

Shares of LEXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LEXX) was last updated on 7/25/2024 by MarketBeat.com Staff

From Our Partners